Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course radiotherapy followed by camrelizumab with or without CAPOX for locally advanced rectal cancer
ChiCTR2300072471Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of camrelizumab, capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Pathological complete remission rate. Started Jun 2023; status: recruiting.
02
Drugs
camrelizumabcapecitabineoxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR2300072471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072471.